Geftinat 250mg
Molecular Salt: Gefitinib
Geftinat 250 mg (Gefitinib) is specified against a type of lung cancer (non-small cell) wherein cells are mutated in epidermal growth factor receptor (EGFR). EGFR is expressed on the cell surface of these cancerous cells. Geftinat 250 mg (Gefitinib) selectively targets the proteins that are mutated in these cells. It is taken orally as a 250 mg dose once daily with or without food.
Additional properties of Geftinat 250 mg (Gefitinib):
Once Geftinat 250 mg (Gefitinib) enters our system, it takes around 3 to 7 hours for absorbing at least 60% of the drug. With 90% binding affinity with cancerous cells, Gefitinib carries out anti-cancer activities by metabolizing in the liver. Finally, more than 50% of the drug gets excreted out of the system within 2 days.
Other warnings before taking Gefitinib:
The healthcare provider should be notified regarding,
- Lung or breathing problems
- Liver complications
- Difficulties in visualizing
- Pregnancy
- Breastfeeding
- Proton pump inhibitors, antacids or other medicines
Most common side-effects:
- Diarrhea
- Skin reactions (rashes, dry skin and itching)
- Sickness
- Ulcers on the mouth
- Loss of appetite
Note: These are not all side-effects of Gefitinib, inform your healthcare provider if you witness others.
Natco Pharma
Tablet (250 mg)
Single Pack Unit
Store below 30°C
Product Enquiry
Submit an enquiry for wholesale sourcing, pricing, and cold-chain delivery. Our team responds within 24 hours.
Clinical Advisory & Import Compliance
Disclaimer: Gandhi Medicos is a clinical specialty supplier and exporter. All enquiries are subject to valid licensing verification and import permits standard under target jurisdiction guidelines.
Storage Warning: Biological injectables, biosimilars, and active oncology agents are flagged as temperature-sensitive cargo and are packed strictly inside thermal containers coupled with real-time digital temperature tags.